Trial Profile
A Phase IB Study to Evaluate the Effect of RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer Lesions Using 16α-18F-Fluoro-17β-Estradiol Positron Emission Tomography Imaging
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Aug 2022
Price :
$35
*
At a glance
- Drugs Elacestrant (Primary)
- Indications Advanced breast cancer; Carcinoma
- Focus Therapeutic Use
- Sponsors Stemline Therapeutics
- 19 May 2020 Status changed from active, no longer recruiting to completed.
- 14 Dec 2019 Results of pooled analysis (n=73) from 2 Phase I trials (NCT02650817, NCT02338349) characterizing the molecular features of the heavily pretreated population in these 2 trials and their correlation with elacestrant response presented at the 42nd Annual San Antonio Breast Cancer Symposium.
- 11 Oct 2019 Planned End Date changed from 1 Sep 2019 to 1 Dec 2019.